Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.
Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, Maroz A, Anderson RF, Patterson AV, Stachelek GC, Glazer PM, Matteucci MD, Hart CP.
Meng F, et al. Among authors: hart cp.
Mol Cancer Ther. 2012 Mar;11(3):740-51. doi: 10.1158/1535-7163.MCT-11-0634. Epub 2011 Dec 6.
Mol Cancer Ther. 2012.
PMID: 22147748